Last reviewed · How we verify
NCT06318559: RIDERS
Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention
NA trial testing 3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy in Cancer of Prostate in 120 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Fondazione del Piemonte per l'Oncologia |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 120 |
| Start date | 29 June 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2027 |
| Sites | 2 locations across Italy |
Drugs / interventions tested
- 3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy
Conditions studied
- Cancer of Prostate — all drugs for Cancer of Prostate →
Sponsor
Fondazione del Piemonte per l'Oncologia — full company profile →
Who can join
Adults 40 to 99, male only, with Cancer of Prostate. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective randomized multicenter study aimed at comparing 3D AI-AR-RARP vs. no 3D, verifying the impact of this new technology on oncological and functional outcomes after the procedure.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Artificial Intelligence 3D Augmented Reality-guided Robotic Prostatectomy Versus Cognitive MRI Intervention: Results of the Prospective Randomized RIDERS Trial.
Porpiglia F, Checcucci E, Volpi G, Stura I, et al · · 2026 · PMID 41087293 · DOI 10.1016/j.eururo.2025.09.4172
Verify or expand the search:
- PubMed search for NCT06318559
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer of Prostate
Currently open trials in the same condition.
- NCT07072728 — Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder · Phase 2 · recruiting
- NCT06554587 — Investigation of Three Biomarkers for the Detection of Prostate Cancer · recruiting
- NCT04887935 — Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer · Phase 1 · recruiting
- NCT05653063 — ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer · recruiting
- NCT05214937 — A Intervention for Reducing Sedentary Behaviour Among Prostate Cancer Survivors · NA · recruiting
Other Fondazione del Piemonte per l'Oncologia trials
Trials by the same sponsor.
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
- NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting
- NCT07494201 — MIMICC Study in Patients With Colorectal Cancer · NA · recruiting
- NCT07479095 — Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic · NA · recruiting
- NCT07507890 — Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06318559 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione del Piemonte per l'Oncologia
- Last refreshed: 19 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06318559.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing